These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 11158863)

  • 21. Vitamin D analogs: new therapeutic agents for secondary hyperparathyroidism.
    Brown AJ; Coyne DW
    Treat Endocrinol; 2002; 1(5):313-27. PubMed ID: 15832485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical management of secondary hyperparathyroidism in chronic renal failure.
    Goodman WG
    Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii2-8. PubMed ID: 12771290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcitriol in the management of secondary hyperparathyroidism of renal failure.
    Daisley-Kydd RE; Mason NA
    Pharmacotherapy; 1996; 16(4):619-30. PubMed ID: 8840368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcitriol oral therapy for the prevention of secondary hyperparathyroidism in patients with predialytic renal failure.
    Panichi V; Andreini B; De Pietro S; Migliori M; Taccola D; Giovannini L; Ferdeghini M; Palla R
    Clin Nephrol; 1998 Apr; 49(4):245-50. PubMed ID: 9582556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Secondary hyperparathyroidism in renal insufficiency. Prevention and therapy].
    Malluche HH; Ritz E
    MMW Munch Med Wochenschr; 1976 Jan; 118(5):129-30. PubMed ID: 814442
    [No Abstract]   [Full Text] [Related]  

  • 26. The dual vitamin D pathways: considerations for adequate supplementation.
    Cronin SC
    Nephrol Nurs J; 2010; 37(1):19-26, 36; quiz 27-8. PubMed ID: 20333900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of metabolic bone disease in the pre-end-stage renal disease setting.
    Coburn JW; Elangovan L
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vitamin D analogs as therapeutic agents: a clinical study update.
    Wu-Wong JR; Tian J; Goltzman D
    Curr Opin Investig Drugs; 2004 Mar; 5(3):320-6. PubMed ID: 15083599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Vitamin D therapy in predialysis renal failure].
    Ando R
    Clin Calcium; 2004 Sep; 14(9):73-7. PubMed ID: 15577115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.
    Rauscher S; Lafrance JP; Pichette V; Bell RZ; Desforges K; Lepage L; Ouellet G; Ouimet D; Leblanc M; Lamarche C; Bezzaoucha S; Vallee M
    Int Urol Nephrol; 2017 Feb; 49(2):325-328. PubMed ID: 27822674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Which vitamin D derivative to prescribe for renal patients.
    Drüeke TB
    Curr Opin Nephrol Hypertens; 2005 Jul; 14(4):343-9. PubMed ID: 15931002
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure].
    Akiba T
    Clin Calcium; 2007 May; 17(5):767-71. PubMed ID: 17471008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prevention and treatment of renal osteodystrophy: present and future].
    Fernández E; Craver L
    Nefrologia; 2006; 26 Suppl 3():19-27. PubMed ID: 17469423
    [No Abstract]   [Full Text] [Related]  

  • 34. Management of disturbed calcium metabolism in uraemic patients: 1. Use of vitamin D metabolites.
    Schömig M; Ritz E
    Nephrol Dial Transplant; 2000; 15 Suppl 5():18-24. PubMed ID: 11073270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?
    Toussaint ND; Damasiewicz MJ
    Nephrology (Carlton); 2017 Mar; 22 Suppl 2():51-56. PubMed ID: 28429545
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
    Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
    Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperparathyroidism in renal failure.
    Br Med J; 1978 Feb; 1(6110):390-1. PubMed ID: 624024
    [No Abstract]   [Full Text] [Related]  

  • 38. New approaches to treatment of secondary hyperparathyroidism.
    Locatelli F; Limardo M; Pontoriero G
    Curr Opin Investig Drugs; 2008 Apr; 9(4):363-70. PubMed ID: 18393103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Falecalcitriol for conventional vitamin D therapy-resistant secondary hyperparathyroidism in a continuous ambulatory peritoneal dialysis patient.
    Tokunaga M; Tamura M; Kabashima N; Serino R; Shibata T; Matsumoto M; Miyamoto T; Miyazaki M; Furuno Y; Takeuchi M; Abe H; Okazaki M; Otsuji Y
    Clin Nephrol; 2008 May; 69(5):393-4. PubMed ID: 18538106
    [No Abstract]   [Full Text] [Related]  

  • 40. [Falecalcitriol as a new therapeutic agent for secondary hyperparathyroidism].
    Morii H
    Clin Calcium; 2005 Jan; 15(1):29-33. PubMed ID: 15632470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.